Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
| ▸ | CBX4 | O00257 | 2/20 | 0.41 |
| ▸ | CBX7 | O95931 | 2/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.41 |
| ▸ | CBX8 | Q9HC52 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.40 |
| ▸ | CPA2 | P48052 | 2/20 | 0.40 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14232442 | 1.00 | REN (0.43) | RENKISS1RCBX4CBX7CDYL2 | |
| SCHEMBL2633292 | 0.87 | GNPAT (0.48) | KISS1RCPA1CPA2CPA4GNPAT | |
| SCHEMBL2633286 | 0.84 | ALDH1A1 (0.50) | RENCPA1CPA2CPA4GNPAT | |
| SCHEMBL10105765 | 0.84 | ALDH1A1 (0.50) | RENCPA1CPA2CPA4GNPAT | |
| SCHEMBL2632699 | 0.83 | CPA1 (0.41) | CPA1CPA2CPA4CTSK | |
| SCHEMBL10105751 | 0.82 | CPA1 (0.47) | BIRC2CPA1CPA2CPA4 | |
| SCHEMBL2632731 | 0.79 | CPA1 (0.50) | CPA1CPA2CPA4CTSK | |
| SCHEMBL2633287 | 0.78 | PSMB5 (0.52) | — | |
| SCHEMBL8281554 | 0.78 | REN (0.62) | RENCTSK | |
| SCHEMBL10105787 | 0.78 | PSMB5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | REN 600/4885KISS1R 3771/4885CBX4 2114/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | REN 600/4885KISS1R 3771/4885CBX4 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.